TME Pharma N.V. ((DE:0N6A)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The clinical study titled An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients aims to evaluate the disease control rate at six weeks for the combination of olaptesed pegol with pembrolizumab and other chemotherapy agents in treating metastatic pancreatic cancer. This study is significant as it seeks to determine the safety, tolerability, and efficacy of these combinations, potentially leading to a larger randomized study.
The interventions being tested are combinations of drugs, including olaptesed pegol and pembrolizumab, with either nanoliposomal irinotecan, 5-FU, and leucovorin, or gemcitabine and nab-paclitaxel. These treatments are intended to improve outcomes for patients with metastatic pancreatic cancer.
This Phase 2 study is designed as an interventional trial with a non-randomized, parallel assignment. It involves single masking, where only the participant is unaware of the treatment allocation. The primary purpose of the study is treatment-focused.
The study was first submitted on May 20, 2021, and the latest update was submitted on June 24, 2025. It is currently not yet recruiting, indicating that patient enrollment has not started. These dates are crucial for tracking the study’s progress and anticipated milestones.
The update on this study could influence TME Pharma N.V.’s stock performance and investor sentiment, as successful outcomes may enhance the company’s competitive position in the oncology market. Investors should also consider the involvement of Merck Sharp & Dohme LLC as a collaborator, which may provide additional credibility and resources.
The study is ongoing, with further details available on the ClinicalTrials portal.